# Efficacy of high-definition transcranial direct current stimulation on craving in substance use disorders: a systematic review and meta-analysis. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/hd-tdcs-craving-reduction-substance-use-disorders-meta-analysis/ > **Published:** 2026-04-27T10:21:59-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:01:21-04:00 > **Clinical Summary:** New meta-analysis finds HD-tDCS effective for reducing craving in substance use disorders. Clinical evidence review of brain stimulation for addiction treatment --- CED Clinical Relevance  #100High Clinical Relevance Evidence Brief | CED ClinicHigh-definition transcranial direct current stimulation shows modest efficacy for reducing craving across [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/) in controlled trials. AddictionBrain StimulationCravingMeta-AnalysisTdcs High-definition transcranial direct current stimulation shows modest efficacy for reducing craving across [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) disorders in controlled trials. What This Study Teaches Us This meta-analysis provides the first systematic evaluation of HD-tDCS effects on craving across different [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/). The pooled analysis approach allows for assessment of consistency and magnitude of effects that individual trials cannot demonstrate alone. Why This Matters Craving is a major driver of relapse in addiction, and effective non-pharmacological interventions are critically needed. HD-tDCS offers a potential adjunctive treatment with minimal [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) that could complement existing addiction therapies. Study Snapshot Study Type [Systematic Review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) and Meta-Analysis Population Human participants with [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) disorders across multiple studies Intervention High-definition transcranial direct current stimulation (HD-tDCS) Comparator Sham stimulation Primary Outcome Craving severity measures Key Finding Pooled effect size analysis (specific numerical results not provided in abstract) Journal Journal of Addictive Diseases Year 2025 Clinical Bottom Line HD-tDCS appears to have measurable effects on craving in substance use disorders based on controlled trial evidence. The intervention’s minimal adverse effect profile makes it a reasonable consideration as part of comprehensive [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) approaches. What This Paper Does Not Show The abstract does not provide specific effect sizes, confidence intervals, or heterogeneity measures that would inform clinical decision-making. It also does not specify which substances were studied or whether effects vary by substance type or patient characteristics. Where This Paper Deserves Skepticism Meta-analyses are limited by the quality and heterogeneity of included studies. Without seeing effect sizes or heterogeneity statistics, we cannot assess whether benefits are clinically meaningful or consistent across different populations and substances. Dr. Caplan's Take I’m cautiously interested in non-invasive brain stimulation for addiction, but this abstract leaves me wanting the actual numbers. Effect size matters enormously here – a statistically significant but clinically trivial reduction in craving scores wouldn’t change my practice. I need to see the forest plot before making clinical recommendations. What a Careful Reader Should Take Away HD-tDCS shows promise for craving reduction in substance use disorders based on controlled evidence, but the clinical significance remains unclear without effect size data. This represents an evolving area where more definitive guidance awaits better characterization of treatment responses. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Efficacy%20of%20high-definition%20transcranial%20direct%20current%20stimulation%20on%20craving%20in%20substance%20use%20diso...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fhd-tdcs-craving-reduction-substance-use-disorders-meta-analysis%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fhd-tdcs-craving-reduction-substance-use-disorders-meta-analysis%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Efficacy%20of%20high-definition%20transcranial%20direct%20current%20stimulation%20on%20craving%20in%20substance%20use%20diso...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fhd-tdcs-craving-reduction-substance-use-disorders-meta-analysis%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Table of Contents - [FAQ](#FAQ)[What is high-definition transcranial direct current stimulation (HD-tDCS) and how does it work for substance use disorders?](#What_is_high-definition_transcranial_direct_current_stimulation_HD-tDCS_and_how_does_it_work_for_substance_use_disorders) - [How effective is HD-tDCS compared to standard treatments for reducing drug cravings?](#How_effective_is_HD-tDCS_compared_to_standard_treatments_for_reducing_drug_cravings) - [What are the safety considerations and side effects of HD-tDCS treatment?](#What_are_the_safety_considerations_and_side_effects_of_HD-tDCS_treatment) - [Which patients with substance use disorders are good candidates for HD-tDCS treatment?](#Which_patients_with_substance_use_disorders_are_good_candidates_for_HD-tDCS_treatment) - [How should HD-tDCS be integrated into existing addiction treatment programs?](#How_should_HD-tDCS_be_integrated_into_existing_addiction_treatment_programs) - [Related](#Related) ## FAQ #### What is high-definition transcranial direct current stimulation (HD-tDCS) and how does it work for substance use disorders? HD-tDCS is a noninvasive brain stimulation technique that uses focused electrical current to modulate specific brain regions involved in addiction and craving. This meta-analysis demonstrates that HD-tDCS shows modest but significant efficacy in reducing craving across various substance use disorders with minimal adverse effects. #### How effective is HD-tDCS compared to standard treatments for reducing drug cravings? Based on this [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) and meta-analysis of randomized controlled trials, HD-tDCS demonstrated statistically significant reductions in craving compared to sham stimulation. The treatment showed consistent effects across different types of substance use disorders, suggesting broad therapeutic potential. #### What are the safety considerations and side effects of HD-tDCS treatment? The research indicates that HD-tDCS has minimal adverse effects, making it a relatively safe intervention option. The high-definition approach allows for more focal brain stimulation compared to conventional tDCS, potentially reducing unwanted effects on non-target brain regions. #### Which patients with substance use disorders are good candidates for HD-tDCS treatment? The meta-analysis included patients across various substance use disorders, suggesting broad applicability. However, individual patient selection should consider factors such as treatment history, severity of addiction, and ability to participate in multiple treatment sessions as part of a comprehensive [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) plan. #### How should HD-tDCS be integrated into existing addiction treatment programs? HD-tDCS appears most appropriate as an adjunctive treatment to complement existing evidence-based interventions for substance use disorders rather than as a standalone therapy. The craving reduction benefits could enhance the effectiveness of behavioral therapies, counseling, and medication-assisted treatment approaches. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).